{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:06:44Z","timestamp":1790770004017,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,26]],"date-time":"2015-02-26T00:00:00Z","timestamp":1424908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.010","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T16:12:17Z","timestamp":1439914337000},"page":"S167-S169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"S","title":["Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1"],"prefix":"10.1016","volume":"15","author":[{"given":"Michael Y.","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"George F.","family":"Widhopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina C.N.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitzgerald","family":"Lao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Sadarangani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Cavagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Prussak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.010_bib1","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009175","article-title":"The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction","volume":"6","author":"Green","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.clml.2015.02.010_bib2","doi-asserted-by":"crossref","first-page":"26181","DOI":"10.1016\/S0021-9258(18)35733-8","article-title":"A\u00a0novel family of cell surface receptors with tyrosine kinase-like domain","volume":"267","author":"Masiakowski","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2015.02.010_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/RRS-120018757","article-title":"Expression and function of the Ror-family receptor tyrosine kinases during development: lessons from genetic analyses of nematodes, mice, and humans","volume":"23","author":"Yoda","year":"2003","journal-title":"J\u00a0Recept Signal Transduct Res"},{"key":"10.1016\/j.clml.2015.02.010_bib4","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.leukres.2011.06.021","article-title":"ROR1 is expressed on hematogones (non-neoplastic human B-lymphocyte precursors) and a minority of precursor-B acute lymphoblastic leukemia","volume":"35","author":"Broome","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.010_bib5","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1084\/jem.194.11.1625","article-title":"Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B\u00a0cells","volume":"194","author":"Klein","year":"2001","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2015.02.010_bib6","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.194.11.1639","article-title":"Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia","volume":"194","author":"Rosenwald","year":"2001","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.clml.2015.02.010_bib7","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1073\/pnas.0712148105","article-title":"Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a","volume":"105","author":"Fukuda","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.010_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.1308374111","article-title":"ROR1 can interact with TCL1 and enhance leukemogenesis in Emu-TCL1 transgenic mice","volume":"111","author":"Widhopf","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.010_bib9","doi-asserted-by":"crossref","first-page":"e31127","DOI":"10.1371\/journal.pone.0031127","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.02.010_bib10","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1158\/0008-5472.CAN-10-2662","article-title":"Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis","volume":"71","author":"Gentile","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.010_bib11","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1002\/ijc.28879","article-title":"The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells","volume":"135","author":"Gentile","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2015.02.010_bib12","doi-asserted-by":"crossref","first-page":"e21018","DOI":"10.1371\/journal.pone.0021018","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2015.02.010_bib13","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"Baskar","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.clml.2015.02.010_bib14","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.clml.2015.02.010_bib15","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2010-05-283309","article-title":"The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor","volume":"116","author":"Hudecek","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.010_bib16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/leu.2014.199","article-title":"Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia","volume":"29","author":"Mani","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.010_bib17","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/leu.2011.362","article-title":"Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells","volume":"26","author":"Daneshmanesh","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.010_bib18","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","article-title":"The onco-embryonic antigen ROR1 is expressed by a variety of human cancers","volume":"181","author":"Zhang","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2015.02.010_bib19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.010_bib20","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2015.02.010_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1586\/17474086.2014.963048","article-title":"Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art","volume":"7","author":"Robak","year":"2014","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2015.02.010_bib22","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1158\/0008-5472.CAN-12-3832","article-title":"Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis","volume":"73","author":"Cui","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.010_bib23","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.clml.2015.02.010_bib24","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T16:02:45Z","timestamp":1653062565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":24,"alternative-id":["S2152265015000397"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}